Stanley-Laman Group’s Tandem Diabetes Care TNDM Stock Holding History

Stanley-Laman Group’s Portfolio TNDM Stock Details TNDM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-19,191	Closed	-$1.14M	–	292
2022 Q2	$1.14M	Sell	19,191 -266	-1%	-$21.8K	0.2%	151
2022 Q1	$2.26M	Buy	19,457 +2,433	+14%	+$284K	0.31%	115
2021 Q4	$2.56M	Buy	+17,024	New	+$2.3M	0.3%	112

Other funds holding TNDM

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

CIP

Champlain Investment Partners Burlington, Vermont $7.88B AUM 6.82% 1-Year Est. Return

BCM

Brown Capital Management Baltimore, Maryland $704M AUM 6.25% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Eminence Capital New York $4.36B AUM 3.1% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Stanley-Laman Group's TNDM Position: Q3 2022 in Review

Stanley-Laman Group sold out of Tandem Diabetes Care (TNDM) in Q3 2022, closing a stake of 19,191 shares — an estimated $1.14M sold.

Stanley-Laman Group first reported a position in TNDM in Q4 2021 and held it in 3 quarters. The position peaked at $2.56M in Q4 2021. 299 funds tracked by Wall St. Rank hold TNDM as of Q3 2022.

Stanley-Laman Group reported no remaining Tandem Diabetes Care position as of Q3 2022 after selling out during the quarter.
Stanley-Laman Group sold 19,191 Tandem Diabetes Care shares in Q3 2022, an estimated $1.14M.
Stanley-Laman Group first reported a position in Tandem Diabetes Care in Q4 2021 and held it in 3 quarters.
Stanley-Laman Group's Tandem Diabetes Care position peaked at $2.56M in Q4 2021.
299 funds tracked by Wall St. Rank held Tandem Diabetes Care as of Q3 2022.

Based on Stanley-Laman Group's 13F filing for Q3 2022, filed 18 Oct 2022.